Keros Therapeutics, Inc. (KROS) Operating Margin
- Operating margin · 12 months: Value -675.82%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -675.82% | Operating income / revenue. Period ending 2026-06-30. $-101.47M ÷ $15.01M × 100 ≈ -675.82% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -101.47M USD | Operating Income (Loss) |
| Revenue | 15.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 75.86M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-101.47M | $15.01M | (m) | $75.86M | (m) | -675.82% |
| 2026-03-31 | $-110.35M | $33.18M | (m) | $97.03M | (m) | -332.55% |
| 2025-12-31 | $67.57M | $244.06M | (m) | $129.64M | (m) | 27.69% |
| 2025-09-30 | $43.59M | $246.72M | (m) | $157.36M | (m) | 17.67% |
| 2025-06-30 | $312.00K | $232.84M | (m) | $187.07M | (m) | 0.13% |
| 2025-03-31 | $-10.31M | $214.71M | (m) | $184.08M | (m) | -4.80% |
| 2024-12-31 | $-210.83M | $3.55M | (m) | $173.63M | (m) | -5938.96% |
| 2024-09-30 | $-204.03M | $651.00K | (m) | $165.49M | (m) | -31341.63% |
| 2024-06-30 | $-188.66M | $271.00K | (m) | $150.41M | (m) | -69615.13% |
| 2024-03-31 | $-179.56M | $234.00K | (m) | $142.43M | (m) | -76732.91% |
| 2023-12-31 | $-169.94M | $151.00K | (m) | $135.26M | (m) | -112543.71% |
| 2023-09-30 | $-155.45M | $8.00K | (m) | $122.63M | (m) | -1943075.00% |
| 2023-06-30 | $-140.14M | (m) | (m) | $109.53M | (m) | (m) |
| 2023-03-31 | $-129.53M | (m) | (m) | $100.28M | (m) | (m) |
| 2022-12-31 | $-114.79M | $0.00 | (m) | $87.27M | (m) | (m) |
| 2022-09-30 | $-87.70M | $20.00M | (m) | $81.23M | (m) | -438.48% |
| 2022-06-30 | $-79.92M | $20.00M | (m) | $75.02M | (m) | -399.58% |
| 2022-03-31 | $-64.73M | (m) | (m) | $61.73M | (m) | (m) |
| 2021-12-31 | $-56.37M | $20.10M | (m) | $55.14M | (m) | -280.46% |
| 2021-09-30 | $-64.80M | $100.00K | (m) | $45.98M | (m) | -64798.00% |
| 2021-06-30 | $-56.55M | $100.00K | (m) | $39.55M | (m) | -56549.00% |
| 2021-03-31 | $-51.92M | (m) | (m) | $36.83M | (m) | (m) |
| 2020-12-31 | $-46.66M | $0.00 | (m) | $33.86M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-10.56M | $10.00M | (m) | $17.38M | (m) | -105.63% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |